It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been significant advances in the understanding of MPNs, including underlying genetic changes that drive the development of MPNs. This has led to research focusing on targeted therapy and increased the availability of new treatment options.

The post MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls appeared first on VJHemOnc.

A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of innovative therapies which has generated rapid progress in the management of CLL.

In this podcast, John Gribben of Barts Cancer Institute, London, UK, chairs an insightful discussion with Barbara Eichhorst of the University of Cologne, Cologne, Germany, Susan O’Brien of the University of California, Irvine, CA, and Matthew Davids of Dana-Farber Cancer Institute, Boston, MA, on the latest CLL updates from the recent Virtual ASCO and EHA 2020 Meetings. The speakers discuss frontline therapy for CLL, BTK inhibitors, novel combination therapies and the importance of measurable residual disease (MRD) assessment. Treatment sequencing and novel therapies, in particular CAR T-cell approaches were also discussed.

The post The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies appeared first on VJHemOnc.

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer post-infection outcomes. In this podcast, Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, chairs an exciting discussion with Jan Philipp Bewersdorf, Yale University and Yale Cancer Center, New Haven, CT, Rory Shallis, MD, Yale University and Yale Cancer Center, New Haven, CT, and John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY. These speakers discuss their recent collaborative publication in Lancet Hematology, evaluating the management of adult patients with acute leukemias and myeloid neoplasms in the COVID-19 era.

The post The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation appeared first on VJHemOnc.

The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment of the disease. 

In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX,  chairs a discussion with Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, and Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia. The spreakers debate the key updates in the treatment of AML from the recent ASCO and EHA 2020 virtual meetings including emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML.

The post The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML appeared first on VJHemOnc.

Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater understanding of the disease and treatment approaches, there can be better outcomes for patients. In this podcast, Carolina Vincente-Duenas from the Institute of Biomedical Research, Salamanca, Spain, Talha Badar of the Medical College of Wisconsin, Milwaukee, WI, and Christina Peters of St. Anna Children’s Hospital, Vienna, Austria, discuss key updates in ALL presented at this year’s virtual European Hematology Association (EHA) 2020 congress.

The post Key updates in ALL at EHA 2020 appeared first on VJHemOnc.